Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Numares AG currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is assigned to 1 distinct examiner and a distinct art unit, reflecting a concentrated intellectual property strategy. The examiner overseeing this matter is SCHULTZHAUS, JANNA NICOLE, who is the busiest examiner for the portfolio.
The workload for SCHULTZHAUS, JANNA NICOLE consists of a busiest examiner pending action. This specific action represents the total current pending office actions for Numares AG in this sector. Because there is a distinct examiner involved, the prosecution team can focus on the preferences and historical patterns of this individual.
The concentration within a distinct art unit simplifies the technical requirements for the legal team. Practitioners can tailor their arguments to the specific standards of that unit without worrying about conflicting interpretations from other examiners. Success in this portfolio depends on the effective resolution of the application currently under review. By focusing on the specific feedback from SCHULTZHAUS, JANNA NICOLE, the company can navigate its current patent challenges in the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHULTZHAUS, JANNA NICOLE | 1 | 35.4% | +38.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16654828 | Method for Characterizing a Sample by Data Analysis | SCHULTZHAUS, JANNA NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16654828 | Method for Characterizing a Sample by Data Analysis | SCHULTZHAUS, JANNA NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16654828 | Method for Characterizing a Sample by Data Analysis | SCHULTZHAUS, JANNA NICOLE | 1685 | §101§112 | Final Rejection | — | Pending | Oct 16, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNumares AG has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Janna Nicole Schultzhaus has the most, with 1 of Numares AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
